Advertisement

Topics

Neratinib (PB272)

12:02 EDT 19th August 2018 | BioPortfolio

Puma's investigational drug PB272 (neratinib). Puma is currently developing PB272 for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Neratinib (PB272) market research data and corporate reports here